Application of STAT1 / 3 inhibitor in preparation of medicine for improving cis-platinum drug resistance

CN119015271APending Publication Date: 2024-11-26WEST CHINA HOSPITAL SICHUAN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310586200.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Cisplatin anticancer drugs are prone to drug resistance and toxic side effects in long-term treatment. The prior art has failed to effectively use STAT1/3 inhibitors to regulate their repair of DNA damage to improve their efficacy.

Method used

A STAT1/3 inhibitor, including nifuzid, was designed in combination with cisplatin, by targeting STAT1 and STAT3 proteins, reducing its activity, combining small molecule inhibitors CBL0137 and Nifuroxazide with cisplatin, enhancing Sensitivity to drug-resistant cells.

Benefits of technology

It significantly enhances the killing effect of cisplatin on drug-resistant non-small cell lung cancer cells, provides a new idea to overcome tumor drug resistance, especially for the treatment of cisplatin-resistant lung cancer and non-small cell lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015271A_ABST
    Figure CN119015271A_ABST
Patent Text Reader

Abstract

The invention provides an application of an STAT1 / 3 inhibitor in preparation of a medicine for improving cis-platinum drug resistance, and an application of nifurazil and cis-platinum as STAT1 / 3 inhibitors in preparation of a combined medicine for treating tumors with cis-platinum drug resistance. The key DNA damage response protein for regulating and controlling the non-small cell lung cancer cell cis-platinum drug resistance is designed and determined, the key small molecule inhibitor nifurazil for enhancing the drug effect of cis-platinum on drug-resistant cells is screened out, the nifurazil is combined with cis-platinum to be used for treating cis-platinum drug-resistant tumors, the synergistic interaction effect is achieved, and the application prospect is wide. A new thought is provided for overcoming the tumor drug resistance.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Cited By

  • Small molecule compound CBL0137 for treating skin T cell lymphoma and application thereof

    CN121081461A